A small molecule glucosidase inhibitor used for treating diabetes. absorption blocker, glyset, antidiabetic drug



Oral anti-diabetic drug





Commercial Name

Glyset (United States), Diastabol (Germany), Plumarol (Spain)

Combination Drug(s)

Miglitol tablets may be combined with sulfonylureas and metformin in fixed doses. 

Other Synonyms



(2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl) piperidine-3,4,5-triol

Ligand Code in PDB


3D Structure of miglitol bound to target protein Maltase Glucoamylase (MGAM)

PDB ID 3l4w


Table 1. Basic profile of miglitol

Figure 1. 2D and 3D structure of miglitol

Drug Information: 

Chemical Formula


Molecular Weight

207.22 g/mol

Calculated Predicted Partition Coefficient: cLogP


Calculated Predicted Aqueous Solubility: cLogS


Solubility (in water)

610.0 mg/mL (sparingly soluble)

Predicted Topological Polar Surface Area (TPSA)

104.39 Å2

Table 2. Chemical and physical properties of miglitol (DrugBank).

Drug Target: 

Miglitol is an orally active antidiabetic drug that inhibits the enzymatic activity of glycoside hydrolase enzymes, known as alpha glucosidases. These enzymes breakdown complex carbohydrates, e.g., disaccharides, oligosaccharides and polysaccharides into glucose. One of the molecular targets of miglitol is maltase glucoamylase (MGAM).  This enzyme is responsible for hydrolysis of polysaccharides into glucose (Sim et al., 2010). Miglitol works by delaying digestion of carbohydrates, thereby lowering postprandial hyperglycemia (high blood glucose level after meals), and promoting glycemic control in diabetic patients (DrugBank).

Learn more about the targets of miglitol here.

Drug-Target Complex: 

Human maltase-glucoamylase (MGAM) enzyme is composed of 1867 residues and contains two homologous catalytic subunits. The N-terminal domain (residues 1-868) is called NtMGAM  and C-terminal domain (residues 955-1867) is called CtMGAM. Both subunits carry out the same catalytic reaction but differ in their distinct specificity for varying lengths of malto-oligosaccharides (Sim et al., 2008). In this article, we will discuss the co-crystal structure of NtMGAM complexed with miglitol.

The N-terminal MGAM subunit (868 residues) is comprised of five major structural domains (Sim et al., 2008):

  • a trefoil Type-P domain (residues 1-51)
  • an N-terminal β-sandwich domain (residues 52-269)
  • a catalytic (β/α)8 barrel domain (residues 270-651) with two inserted loops protruding out between β3 and α3 and between β4 and α4, respectively
  • a proximal C-terminal domain (residues 652-730)
  • a distal C-terminal domain (residues 731-868)

The overall structure of NtMGAM complexed with miglitol is shown in Figure 2. The five domains are color coded.


Figure 2.  Overall structure of human N-terminal MGAM, complexed with miglitol. The enzyme is shown in ribbon representation highlighting the N- and C-termini, and various regions of the protein - trefoil Type-P domain (pink), an N-terminal β-sandwich domain (yellow), catalytic domain (orange), proximal C-terminal domain(green) and distal C-terminal domain (violet). Miglitol is shown in ball-and-stick representation in the figure (PDB ID 3l4w; Sim et al., 2010).

Miglitol is a small molecule that occupies the -1 sugar subsite. Substrate hydrolysis normally occurs between the -1 and +1 subsites. A close up view of the active site shows miglitols as a green stick figure (Figure 3). Several hydrophobic residues Trp441, Met444, Trp539, and Phe575, lining the subsite -1 (shown as thin stick figures in Figure 3) contribute to hydrophobic interactions with miglitol, whereas other nearby residues form a network of hydrogen bonds with the enzyme inhibitor.


Figure 3. Close up view of the active site of NtMGAM (blue-boxed region in Figure 2). The surface of the active site of NtMGAM is shown in grey. Miglitol is shown as a stick figure, color-coded by atom type (C: green; N: blue; O: red). The sugar subsites -1, +1 are shown with purple and blue arcs respectively. (PDB ID 3l4w; Sim et al., 2010). Neighboring enzyme residues within 3.5Å of miglitol are show in brown

Close examination of the co-crystal structure shows that miglitol binds to NtMGAM via hydrophobic and hydrogen bonding interactions (Figures 3 and 4).  Miglitol makes extensive hydrogen bonding interactions (represented as blue lines) with the enzyme active site residues Asp327, Arg526, His600 (shown as a stick figure in Figure 4), catalytic nucleophile Asp443, and acid/base residue Asp542 (shown in ball-and-stick representation in Figure 4), and neighboring water molecules.  This structure demonstrates that miglitol occludes the active site of MGAM, and prevents substrate binding to delays carbohydrate digestion.


Figure 4. Hydrogen bonding interactions (blue lines) between miglitol (shown as a stick figure, color-coded by atom type - C: green; N: blue; O: red) and residues of NtMGAM. The catalytic nucleophile Asp is labeled in red and the acid/base residue Asp in blue and shown in ball and stick representation, while other enzyme residues are shown as stick figures. Miglitol occupies the −1 sugar subsite of the enzyme. (PDB ID 3l4w; Sim et al., 2010).

Pharmacologic Properties and Safety: 




Bioavailability (%)

100% (25 mg dose) or 50-70% (100 mg dose)  

(Drugs.com, 2016)

IC50 (nM)

6000 nM


Ki (nM)

1000 nM


Half-life (hrs)

2-3 hours

(Drugs.com, 2016)

Duration of Action

2 hours

(Drugs.com, 2016)


Human intestinal absorption



P-glycoprotein (P-gp)



No metabolites have been detected in plasma, urine or feces, indicating a lack of either systemic or pre-systemic metabolism.

(Drugs.com, 2016)


>95% of the 25 mg dose is recovered in the urine within 24 hours.

(Drugs.com, 2016)

AMES Test (Carcinogenic Effect)

0.79 (non AMES toxicity)


hERG Safety Test (Cardiac Effect)

0.5797 (weak inhibitor)


Liver Toxicity

Liver injury from miglitol is rare if it even occurs.


Table 3. Pharmacokinetics: ADMET of Miglitol

Miglitol remains unchanged and is eliminated by renal excretion (Drugs.com, 2016).

Drug Interactions and Side Effects: 

Miglitol is non-carcinogenic. According to the National Institutes of Health, serum aminotransferase elevations (indicators of hepatic injury) were no more common with miglitol than with a placebo. Miglitol is not extensively metabolized in the liver, so it is expected that miglitol does not impair or affect hepatic function. Since its approval and clinical use, there have been no reports of clinically apparent liver injury linked to miglitol. In addition, there were no reports of liver injury from patients who were on acarbose but switched to miglitol.




Total Number of Drugs Interactions

629 drugs

(Drugs.com, 2016)

Major Drug Interactions


(Drugs.com, 2016)

Alcohol/Food Interaction(s)

moderate interaction with alcohol (ethanol)

(Drugs.com, 2016)

Disease Interaction(s)

diabetic ketoacidosis (major), intestinal disease (major) and renal dysfunction (major)

(Drugs.com, 2016)

On-site Binding Side Effects

hypoglycemia, constipation, nausea, diarrhea, gastrointestinal disorders, intestinal obstruction, abdominal pain, abdominal bloating


Off-site Binding Side Effects

skin rash and decreased serum iron levels

(Drugs.com, 2016)

CYP Interactions



Table 4. Drug Interactions and Side Effects of Miglitol 

Regulatory Approvals/Commercial: 

Developed by Pharmacia & Upjohn Company LLC, and approved by the USFDA on December 18, 1996, Glyset (miglitol) is administered orally and is available in 25, 50 and 100 mg tablets (Drugs.com, 2016). Miglitol may be used as monotherapy or with other diabetic medication, such as insulin. The initial dose is 25 mg three times a day, usually taken with the first bite of each meal, followed by a gradual increase to a maximum of 100 mg. Adjustments may be necessary, depending on the patient’s HbA1c or if the patient exhibit severe gastrointestinal (GI) effects (Drugs.com, 2016). According to DrugBank, a Glyset 25 mg tablet costs $1.11; 50 mg tablet, $1.24; and 100 mg tablet $1.46.






Food and Drugs Administration


National Institutes of Health (NIH)


Table 6. Links to Relevant Resources


Miglitol, DrugBank. http://www.drugbank.ca/drugs/DB00491

Miglitol, National Institutes of Health. https://livertox.nih.gov/Miglitol.htm

Miglitol: Indications, Side Effects, Warnings - Drugs.com. https://www.drugs.com/cdi/miglitol.html

Miglitol, PubChem Compound Database; CID=441314, https://pubchem.ncbi.nlm.nih.gov/compound/441314

Sim, L. Quezada-Calvillo, R., Sterchi, E.E., Nichols, B.L. and Rose D.R. (2008) Human Intestinal Maltase–Glucoamylase: Crystal Structure of the N-Terminal Catalytic Subunit and Basis of Inhibition and Substrate Specificity. Journal of Molecular Biology 375,  782-92. doi: 10.1016/j.jmb.2007.10.069.

Sim, L., Jayakanthan, K., Mohan, S., Nasi, R., Johnston, B.D., Pinto, B.M. and Rose, D.R. (2010) New Glucosidase Inhibitors from an Ayurvedic Herbal Treatment for Type 2 Diabetes: Structures and Inhibition of Human Intestinal Maltase-Glucoamylase with Compounds from Salacia Reticulata. Biochemistry 49, 443-51. doi: 10.1021/bi9016457.


August 2019, Kayla Tinio, Jennifer Jiang, and Dr. Sutapa Ghosh ; Reviewed by Dr. Stephen K. Burley
doi: 10.2210/rcsb_pdb/GH/DM/drugs/gi/miglitol